Oslo, 12 December 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker:
"NAVA") hereby announces that an extraordinary general meeting of Navamedic will
be held on 7 January 2026 at 12:00 CET in order to amend the composition of the
board of directors of the Company.

The  extraordinary general meeting of the Company will be held at the Company's
offices at Henrik Ibsens gate 100, 0255 Oslo, Norway. Registration of attendance
must be received no later than 5 January 2026 at 12:00 CET.

Shareholders may vote in advance, or submit a proxy, with or without voting
instructions, by 5 January 2026 at 12:00 CET.

The notice of the extraordinary general meeting, including agenda, proposed
resolutions, registration form and a form of proxy and other information, is
enclosed hereto. Please see the Company's website:
https://navamedic.com/investors/general-meeting/ for other relevant
documentation.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880, e-mail:
kathrine@navamedic.com
Pål Zimmermann Vonen, Director of Group Accounting, Mobile: +47 97 97 92 91, e
-mail: pal.vonen@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

kga@navamedic.com